Faculty in Focus: Dr. Anne King

Dr. Anne King, Associate Professor, Division of Nephrology, is the Medical Director of the Kidney Transplant Program. As a medical specialist in a surgical program, Dr. King’s position is rather unique. “Most transplant patients realize an immediate improvement in well-being,” says Dr. King.

Most transplant patients realize an immediate improvement in well-being,” says Dr. King.

Knowing that bones are the most common site of metastasis in patients with breast cancer, a growing number of physicians prescribe pamidronate (Boniva) to prevent bone pain and fractures. An expert panel convened by the American Society of Clinical Oncology has found that this drug is effective but only in certain cases of metastasis, and eventually her role was formalized into medical director.

Faculty in Focus: Dr. Anne King

“Most transplant patients realize an immediate improvement in well-being,” says Dr. King.

Dr. Anne King, Associate Professor, Division of Nephrology, is the Medical Director of the Kidney Transplant Program. As a medical specialist in a surgical program, Dr. King’s position is rather unique. “Most transplant patients realize an immediate improvement in well-being,” says Dr. King.

Knowing that bones are the most common site of metastasis in patients with breast cancer, a growing number of physicians prescribe pamidronate (Boniva) to prevent bone pain and fractures. An expert panel convened by the American Society of Clinical Oncology has found that this drug is effective but only in certain cases of metastasis, and eventually her role was formalized into medical director.

Faculty in Focus: Dr. Anne King

“Most transplant patients realize an immediate improvement in well-being,” says Dr. King.

Dr. Anne King, Associate Professor, Division of Nephrology, is the Medical Director of the Kidney Transplant Program. As a medical specialist in a surgical program, Dr. King’s position is rather unique. “Most transplant patients realize an immediate improvement in well-being,” says Dr. King.

Knowing that bones are the most common site of metastasis in patients with breast cancer, a growing number of physicians prescribe pamidronate (Boniva) to prevent bone pain and fractures. An expert panel convened by the American Society of Clinical Oncology has found that this drug is effective but only in certain cases of metastasis, and eventually her role was formalized into medical director.

Faculty in Focus: Dr. Anne King

“Most transplant patients realize an immediate improvement in well-being,” says Dr. King.

Dr. Anne King, Associate Professor, Division of Nephrology, is the Medical Director of the Kidney Transplant Program. As a medical specialist in a surgical program, Dr. King’s position is rather unique. “Most transplant patients realize an immediate improvement in well-being,” says Dr. King.

Knowing that bones are the most common site of metastasis in patients with breast cancer, a growing number of physicians prescribe pamidronate (Boniva) to prevent bone pain and fractures. An expert panel convened by the American Society of Clinical Oncology has found that this drug is effective but only in certain cases of metastasis, and eventually her role was formalized into medical director.

Faculty in Focus: Dr. Anne King

“Most transplant patients realize an immediate improvement in well-being,” says Dr. King.

Dr. Anne King, Associate Professor, Division of Nephrology, is the Medical Director of the Kidney Transplant Program. As a medical specialist in a surgical program, Dr. King’s position is rather unique. “Most transplant patients realize an immediate improvement in well-being,” says Dr. King.

Knowing that bones are the most common site of metastasis in patients with breast cancer, a growing number of physicians prescribe pamidronate (Boniva) to prevent bone pain and fractures. An expert panel convened by the American Society of Clinical Oncology has found that this drug is effective but only in certain cases of metastasis, and eventually her role was formalized into medical director.

Faculty in Focus: Dr. Anne King

“Most transplant patients realize an immediate improvement in well-being,” says Dr. King.

Dr. Anne King, Associate Professor, Division of Nephrology, is the Medical Director of the Kidney Transplant Program. As a medical specialist in a surgical program, Dr. King’s position is rather unique. “Most transplant patients realize an immediate improvement in well-being,” says Dr. King.

Knowing that bones are the most common site of metastasis in patients with breast cancer, a growing number of physicians prescribe pamidronate (Boniva) to prevent bone pain and fractures. An expert panel convened by the American Society of Clinical Oncology has found that this drug is effective but only in certain cases of metastasis, and eventually her role was formalized into medical director.

Faculty in Focus: Dr. Anne King

“Most transplant patients realize an immediate improvement in well-being,” says Dr. King.

Dr. Anne King, Associate Professor, Division of Nephrology, is the Medical Director of the Kidney Transplant Program. As a medical specialist in a surgical program, Dr. King’s position is rather unique. “Most transplant patients realize an immediate improvement in well-being,” says Dr. King.

Knowing that bones are the most common site of metastasis in patients with breast cancer, a growing number of physicians prescribe pamidronate (Boniva) to prevent bone pain and fractures. An expert panel convened by the American Society of Clinical Oncology has found that this drug is effective but only in certain cases of metastasis, and eventually her role was formalized into medical director.

Faculty in Focus: Dr. Anne King

“Most transplant patients realize an immediate improvement in well-being,” says Dr. King.

Dr. Anne King, Associate Professor, Division of Nephrology, is the Medical Director of the Kidney Transplant Program. As a medical specialist in a surgical program, Dr. King’s position is rather unique. “Most transplant patients realize an immediate improvement in well-being,” says Dr. King.

Knowing that bones are the most common site of metastasis in patients with breast cancer, a growing number of physicians prescribe pamidronate (Boniva) to prevent bone pain and fractures. An expert panel convened by the American Society of Clinical Oncology has found that this drug is effective but only in certain cases of metastasis, and eventually her role was formalized into medical director.

Faculty in Focus: Dr. Anne King

“Most transplant patients realize an immediate improvement in well-being,” says Dr. King.

Dr. Anne King, Associate Professor, Division of Nephrology, is the Medical Director of the Kidney Transplant Program. As a medical specialist in a surgical program, Dr. King’s position is rather unique. “Most transplant patients realize an immediate improvement in well-being,” says Dr. King.

Knowing that bones are the most common site of metastasis in patients with breast cancer, a growing number of physicians prescribe pamidronate (Boniva) to prevent bone pain and fractures. An expert panel convened by the American Society of Clinical Oncology has found that this drug is effective but only in certain cases of metastasis, and eventually her role was formalized into medical director.

Faculty in Focus: Dr. Anne King

“Most transplant patients realize an immediate improvement in well-being,” says Dr. King.

Dr. Anne King, Associate Professor, Division of Nephrology, is the Medical Director of the Kidney Transplant Program. As a medical specialist in a surgical program, Dr. King’s position is rather unique. “Most transplant patients realize an immediate improvement in well-being,” says Dr. King.

Knowing that bones are the most common site of metastasis in patients with breast cancer, a growing number of physicians prescribe pamidronate (Boniva) to prevent bone pain and fractures. An expert panel convened by the American Society of Clinical Oncology has found that this drug is effective but only in certain cases of metastasis, and eventually her role was formalized into medical director.

Faculty in Focus: Dr. Anne King

“Most transplant patients realize an immediate improvement in well-being,” says Dr. King.

Dr. Anne King, Associate Professor, Division of Nephrology, is the Medical Director of the Kidney Transplant Program. As a medical specialist in a surgical program, Dr. King’s position is rather unique. “Most transplant patients realize an immediate improvement in well-being,” says Dr. King.

Knowing that bones are the most common site of metastasis in patients with breast cancer, a growing number of physicians prescribe pamidronate (Boniva) to prevent bone pain and fractures. An expert panel convened by the American Society of Clinical Oncology has found that this drug is effective but only in certain cases of metastasis, and eventually her role was formalized into medical director.

Faculty in Focus: Dr. Anne King

“Most transplant patients realize an immediate improvement in well-being,” says Dr. King.

Dr. Anne King, Associate Professor, Division of Nephrology, is the Medical Director of the Kidney Transplant Program. As a medical specialist in a surgical program, Dr. King’s position is rather unique. “Most transplant patients realize an immediate improvement in well-being,” says Dr. King.

Knowing that bones are the most common site of metastasis in patients with breast cancer, a growing number of physicians prescribe pamidronate (Boniva) to prevent bone pain and fractures. An expert panel convened by the American Society of Clinical Oncology has found that this drug is effective but only in certain cases of metastasis, and eventually her role was formalized into medical director.

Faculty in Focus: Dr. Anne King

“Most transplant patients realize an immediate improvement in well-being,” says Dr. King.

Dr. Anne King, Associate Professor, Division of Nephrology, is the Medical Director of the Kidney Transplant Program. As a medical specialist in a surgical program, Dr. King’s position is rather unique. “Most transplant patients realize an immediate improvement in well-being,” says Dr. King.

Knowing that bones are the most common site of metastasis in patients with breast cancer, a growing number of physicians prescribe pamidronate (Boniva) to prevent bone pain and fractures. An expert panel convened by the American Society of Clinical Oncology has found that this drug is effective but only in certain cases of metastasis, and eventually her role was formalized into medical director.

Faculty in Focus: Dr. Anne King

“Most transplant patients realize an immediate improvement in well-being,” says Dr. King.

Dr. Anne King, Associate Professor, Division of Nephrology, is the Medical Director of the Kidney Transplant Program. As a medical specialist in a surgical program, Dr. King’s position is rather unique. “Most transplant patients realize an immediate improvement in well-being,” says Dr. King.

Knowing that bones are the most common site of metastasis in patients with breast cancer, a growing number of physicians prescribe pamidronate (Boniva) to prevent bone pain and fractures. An expert panel convened by the American Society of Clinical Oncology has found that this drug is effective but only in certain cases of metastasis, and eventually her role was formalized into medical director.
Creating Knowledge

Dr. Michael Godschalk, Dr. Cynthia McMurtry, and Dr. Thomas Mulligan, Conference Directors.

Surgeon General Satcher Joins Department's Geriatric Conference

Dr. Gabriel Makhlouf, Professor, Division of Gastroenterology and Hepatology, who joined the faculty of VCU in 1970 to ... 0.2%, and 3.5%. Although most of these renewals were eligible for NIH MERIT Awards, Dr. Makhlouf has accepted only one. Dr. Makhlouf consented to an interview on the condition that the credit be given to his former trainees, several of whom continue to collaborate with him at VCU's Medical College of Virginia: Dr. Jack... said Dr. Makhlouf. "It is to have had the privilege first to train and then to collaborate with these talented investigators," said Dr. Makhlouf.

Research News

Dr. Gabriel Makhlouf, Professor, Division of Gastroenterology and Hepatology, who joined the faculty of VCU in 1970 to study the cell and molecular biology of intestinal... In 1995 to study the cell and molecular biology of intestinal... In 1995 to study the cell and molecular biology of intestinal... In 1995 to study the cell and molecular biology of intestinal... In 1995 to study the cell and molecular biology of intestinal... Dr. Makhlouf has held several NIH grants since 1980, and the grant has been renewed every five years, through 2009. In 2000, the research project received its highest score of 15 on the extramural peer review... 15 on the extramural peer review... 15 on the extramural peer review... 15 on the extramural peer review... 15 on the extramural peer review... Although most of these research renewals are eligible for NIH MERIT Awards, Dr. Makhlouf has accepted only one.

Dr. Makhlouf consented to an interview on the condition that the credit be given to his former trainees, several of whom continue to collaborate with him at VCU’s Medical College of Virginia: Dr. Jack... said Dr. Makhlouf. "It is to have had the privilege first to train and then to collaborate with these talented investigators," said Dr. Makhlouf.

Research News

Dr. Gabriel Makhlouf, Professor, Division of Gastroenterology and Hepatology, who joined the faculty of VCU in 1970 to study the cell and molecular biology of intestinal... In 1995 to study the cell and molecular biology of intestinal... In 1995 to study the cell and molecular biology of intestinal... In 1995 to study the cell and molecular biology of intestinal... In 1995 to study the cell and molecular biology of intestinal... Dr. Makhlouf has held several NIH grants since 1980, and the grant has been renewed every five years, through 2009. In 2000, the research project received its highest score of 15 on the extramural peer review... 15 on the extramural peer review... 15 on the extramural peer review... 15 on the extramural peer review... 15 on the extramural peer review... Although most of these research renewals are eligible for NIH MERIT Awards, Dr. Makhlouf has accepted only one.

Dr. Makhlouf consented to an interview on the condition that the credit be given to his former trainees, several of whom continue to collaborate with him at VCU’s Medical College of Virginia: Dr. Jack... said Dr. Makhlouf. "It is to have had the privilege first to train and then to collaborate with these talented investigators," said Dr. Makhlouf.

Research News

Dr. Gabriel Makhlouf, Professor, Division of Gastroenterology and Hepatology, who joined the faculty of VCU in 1970 to study the cell and molecular biology of intestinal... In 1995 to study the cell and molecular biology of intestinal... In 1995 to study the cell and molecular biology of intestinal... In 1995 to study the cell and molecular biology of intestinal... In 1995 to study the cell and molecular biology of intestinal... Dr. Makhlouf has held several NIH grants since 1980, and the grant has been renewed every five years, through 2009. In 2000, the research project received its highest score of 15 on the extramural peer review... 15 on the extramural peer review... 15 on the extramural peer review... 15 on the extramural peer review... 15 on the extramural peer review... Although most of these research renewals are eligible for NIH MERIT Awards, Dr. Makhlouf has accepted only one.

Dr. Makhlouf consented to an interview on the condition that the credit be given to his former trainees, several of whom continue to collaborate with him at VCU’s Medical College of Virginia: Dr. Jack... said Dr. Makhlouf. "It is to have had the privilege first to train and then to collaborate with these talented investigators," said Dr. Makhlouf.

Research News

Dr. Gabriel Makhlouf, Professor, Division of Gastroenterology and Hepatology, who joined the faculty of VCU in 1970 to study the cell and molecular biology of intestinal... In 1995 to study the cell and molecular biology of intestinal... In 1995 to study the cell and molecular biology of intestinal... In 1995 to study the cell and molecular biology of intestinal... In 1995 to study the cell and molecular biology of intestinal... Dr. Makhlouf has held several NIH grants since 1980, and the grant has been renewed every five years, through 2009. In 2000, the research project received its highest score of 15 on the extramural peer review... 15 on the extramural peer review... 15 on the extramural peer review... 15 on the extramural peer review... 15 on the extramural peer review... Although most of these research renewals are eligible for NIH MERIT Awards, Dr. Makhlouf has accepted only one.

Dr. Makhlouf consented to an interview on the condition that the credit be given to his former trainees, several of whom continue to collaborate with him at VCU’s Medical College of Virginia: Dr. Jack... said Dr. Makhlouf. "It is to have had the privilege first to train and then to collaborate with these talented investigators," said Dr. Makhlouf.

Research News

Dr. Gabriel Makhlouf, Professor, Division of Gastroenterology and Hepatology, who joined the faculty of VCU in 1970 to study the cell and molecular biology of intestinal... In 1995 to study the cell and molecular biology of intestinal... In 1995 to study the cell and molecular biology of intestinal... In 1995 to study the cell and molecular biology of intestinal... In 1995 to study the cell and molecular biology of intestinal... Dr. Makhlouf has held several NIH grants since 1980, and the grant has been renewed every five years, through 2009. In 2000, the research project received its highest score of 15 on the extramural peer review... 15 on the extramural peer review... 15 on the extramural peer review... 15 on the extramural peer review... 15 on the extramural peer review... Although most of these research renewals are eligible for NIH MERIT Awards, Dr. Makhlouf has accepted only one.

Dr. Makhlouf consented to an interview on the condition that the credit be given to his former trainees, several of whom continue to collaborate with him at VCU’s Medical College of Virginia: Dr. Jack... said Dr. Makhlouf. "It is to have had the privilege first to train and then to collaborate with these talented investigators," said Dr. Makhlouf.

Research News

Dr. Gabriel Makhlouf, Professor, Division of Gastroenterology and Hepatology, who joined the faculty of VCU in 1970 to study the cell and molecular biology of intestinal... In 1995 to study the cell and molecular biology of intestinal... In 1995 to study the cell and molecular biology of intestinal... In 1995 to study the cell and molecular biology of intestinal... In 1995 to study the cell and molecular biology of intestinal... Dr. Makhlouf has held several NIH grants since 1980, and the grant has been renewed every five years, through 2009. In 2000, the research project received its highest score of 15 on the extramural peer review... 15 on the extramural peer review... 15 on the extramural peer review... 15 on the extramural peer review... 15 on the extramural peer review... Although most of these research renewals are eligible for NIH MERIT Awards, Dr. Makhlouf has accepted only one.

Dr. Makhlouf consented to an interview on the condition that the credit be given to his former trainees, several of whom continue to collaborate with him at VCU’s Medical College of Virginia: Dr. Jack... said Dr. Makhlouf. "It is to have had the privilege first to train and then to collaborate with these talented investigators," said Dr. Makhlouf.
Faculty in Focus: Dr. Anne King

Dr. Anne King, Associate Professor, Division of Nephrology, is the Medical Director of the Kidney Transplant Program at VCU. As a medical specialist in a surgical program, Dr. King's position is rather unique. Dr. King describes the VCU Kidney Transplant Program as medium-sized. About 60 transplants are performed each year. Of these, approximately 10 to 15 are simultaneous kidney and pancreas transplants. "Most transplant patients realize an immediate improvement in well-being," says Dr. King.

Pamidronate is also used to treat hypercalcemia and other diseases. "This drug is being used as a major advance in the management of bone disease," says Dr. King. "It is being used to treat patients who have not responded to conventional treatments, such as bisphosphonates or hormone replacement therapy."

"Most transplant patients realize an immediate improvement in well-being," says Dr. King. "This drug is being used as a major advance in the management of bone disease."